PharmAust Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II cli… Read more
PharmAust Ltd (ECQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.191x
Based on the latest financial reports, PharmAust Ltd (ECQ) has a cash flow conversion efficiency ratio of -0.191x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-743.90K) by net assets (€3.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmAust Ltd - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how PharmAust Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmAust Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmAust Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anam Electroni
KO:008700
|
-0.061x |
|
Pinago Utama Tbk Pt
JK:PNGO
|
0.052x |
|
Mobile Appliance Inc.
KQ:087260
|
-0.048x |
|
Capital & Regional Plc
PINK:CRPLF
|
0.039x |
|
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret
IS:ATATP
|
-0.291x |
|
DEVEX Resources Ltd
AU:DEV
|
-0.123x |
|
TRJNF
PINK:TRJNF
|
N/A |
|
Exacompta Clairefontaine
PA:ALEXA
|
-0.078x |
Annual Cash Flow Conversion Efficiency for PharmAust Ltd (2014–2023)
The table below shows the annual cash flow conversion efficiency of PharmAust Ltd from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | €3.89 Million | €-1.56 Million | -0.402x | -136.81% |
| 2022-06-30 | €7.84 Million | €-1.33 Million | -0.170x | -60.80% |
| 2021-06-30 | €8.88 Million | €-937.97K | -0.106x | +29.09% |
| 2020-06-30 | €8.53 Million | €-1.27 Million | -0.149x | +28.54% |
| 2019-06-30 | €7.46 Million | €-1.55 Million | -0.208x | +4.06% |
| 2018-06-30 | €7.14 Million | €-1.55 Million | -0.217x | -19.64% |
| 2017-06-30 | €6.92 Million | €-1.26 Million | -0.182x | +42.99% |
| 2016-06-30 | €5.02 Million | €-1.60 Million | -0.318x | -60.75% |
| 2015-06-30 | €8.84 Million | €-1.75 Million | -0.198x | +3.15% |
| 2014-06-30 | €7.76 Million | €-1.59 Million | -0.205x | -- |